Adverse Reaction Reporting and Management

Most patients receiving blood products or components do not experience adverse effects. Others may have mild to severe effects, immediately or delayed for 48 hours. The reporting of adverse reactions provides data that is collected, collated and monitored, ensuring an early warning system to NZBS.

Reactions may arise from individual blood products and particular concern exists for detection of reactions to new or modified products. Reactions may occur with a higher incidence in recipients with a particular clinical condition and be more likely to occur as a result of the effects of another medicine or clinical treatment.

Transfusion-related_Adverse_Reaction_Notification_Form This form is recommended for the notification of adverse reactions to all blood products. Last updated on: 7 Dec 2009 || File size: 144 Kb || Acrobat Reader Required.

Guidelines_for_Management_of_Adverse_Transfusion_Reactions These guidelines are recommendations to clinical staff for the management of adverse transfusion reactions. Last updated on: 17 Oct 2007 || File size: 124 Kb || Acrobat Reader Required.

Notification_of_Suspected_Adverse_Reaction_to_Fractionated_Blood_Product Please use this form for reporting reactions to fractionated blood products. The process for doing so is described in the document below, Last updated on: 24 Aug 2009 || File size: 45 Kb || Acrobat Reader Required.

Managing_Notifications_Adverse_Reactions_to_Fractionated_Blood_Prod This document describes the process to be followed when reporting reactions to fractionated blood products. Last updated on: 3 Sep 2009 || File size: 33 Kb || Acrobat Reader Required.